GlassScriptPhysician profile
Ignatius C Medani
NPI 1295831659
$592.40
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $64.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $133.87 | 2019-2020 | |
| Nevro Corp. | $113.48 | 2019 | |
| Merck Sharp & Dohme LLC | $50.89 | 2019 | |
| Daiichi Sankyo INC. | $48.42 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.99 | 2019 | |
| Abbvie INC. | $35.90 | 2020 | |
| Medline Industries LP | $30.22 | 2019 | |
| Zyla Life Sciences, INC. | $29.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.16 | 2019 | |
| Novo Nordisk INC | $19.49 | 2019 | |
| Boston Scientific Corporation | $16.56 | 2019 | |
| Lilly USA, LLC | $16.53 | 2019 | |
| Biodelivery Sciences International, INC. | $15.55 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignatius Medani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.